Fresh Tracks Therapeutics Initiates Multiple Ascending Dose Portion of Phase 1 Study of DYRK1A Inhibitor FRTX-02
FRTX-02 has been well tolerated in completed SAD cohorts; dosing of remaining SAD cohorts to…
FRTX-02 has been well tolerated in completed SAD cohorts; dosing of remaining SAD cohorts to…
FRTX-02 has been well tolerated in completed SAD cohorts; dosing of remaining SAD cohorts to…
HOUSTON, Sept. 13, 2022 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical…
HOUSTON, Sept. 13, 2022 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical…
Second Fast Track designation for efzofitimod clinical program. Efzofitimod previously received FDA orphan drug designation…
Second Fast Track designation for efzofitimod clinical program. Efzofitimod previously received FDA orphan drug designation…
Standardized methodology demonstrates high presence of placental membrane growth factors in BioStem’s Vendaje® and Vendaje…
Standardized methodology demonstrates high presence of placental membrane growth factors in BioStem’s Vendaje® and Vendaje…
NEW YORK, Sept. 13, 2022 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical…
NEW YORK, Sept. 13, 2022 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical…
NEW YORK and CLEVELAND, Sept. 13, 2022 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO)…
NEW YORK and CLEVELAND, Sept. 13, 2022 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO)…
New director brings big pharma oncology experience and biotech leadership SAN DIEGO and TORONTO, Sept….
New director brings big pharma oncology experience and biotech leadership SAN DIEGO and TORONTO, Sept….
NEW YORK, Sept. 13, 2022 (GLOBE NEWSWIRE) — Better Choice Company Inc. (NYSE American: BTTR)…
NEW YORK, Sept. 13, 2022 (GLOBE NEWSWIRE) — Better Choice Company Inc. (NYSE American: BTTR)…
ABILITY Study will evaluate MDNA11, a highly selective long-acting IL-2 Superkine, in combination with Merck’s…
ABILITY Study will evaluate MDNA11, a highly selective long-acting IL-2 Superkine, in combination with Merck’s…
Smart Immune pic Dr Pierre Heimendinger and Dr Frederic Lehmann, CTO and CMO of Smart…
Smart Immune pic Dr Pierre Heimendinger and Dr Frederic Lehmann, CTO and CMO of Smart…